We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
ESHRE guideline update 2022: New perspectives in the management of couples with recurrent pregnancy loss.
- Authors
Cavalcante, Marcelo Borges; Sampaio, Olga Goiana Martins; Câmara, Fernanda Eunice Araújo; Barini, Ricardo
- Abstract
Dear Editor Recently, the Recurrent Pregnancy Loss (RPL) Guideline Development Group (GDG) of the European Society of Human Reproduction and Embryology (ESHRE) published the updated clinical practice guideline for managing couples with RPL.[1] It was with great interest and satisfaction that we observed the inclusion of new recommendations for counseling, evaluation, and treatment of couples who are so fragile, and often, hopeless with their reproductive potential, due to the lack of answers to their questions. Finally, the ESHRE Guideline update included intravenous immunoglobulin as a possible treatment for couples with unexplained RPL (RN #69). Randomized and nonrandomized clinical trials to evaluate the efficacy and safety of immunotherapies for the treatment of RPL have been conducted since the 1980s.
- Subjects
RECURRENT miscarriage; ELECTRONIC cigarettes; PROTEIN S deficiency; HUMAN reproduction
- Publication
American Journal of Reproductive Immunology, 2023, Vol 90, Issue 2, p1
- ISSN
1046-7408
- Publication type
Article
- DOI
10.1111/aji.13739